Skip to main content
Fig. 4 | Respiratory Research

Fig. 4

From: Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial

Fig. 4

Improvement in E-RS total score at Weeks 21–24. Vertical dotted lines indicate quintiles of reversibility at baseline. The MCID of E-RS total score is a ≥ 2-point reduction from baseline [14]. CI, confidence interval; E-RS, Evaluating Respiratory Symptoms-COPD; FEV1, forced expiratory volume in 1 s; FP, fractional polynomial; LS, least squares; MCID, minimal clinically important difference; SAL, salmeterol; UMEC, umeclidinium; VI, vilanterol

Back to article page